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The master cytokine TGF-β mediates tissue fibrosis associated with inflammation and tissue injury. TGF-β induces
fibroblast activation and differentiation into myofibroblasts that secrete extracellular matrix proteins. Canonical TGF-β
signaling mobilizes Smad2 and Smad3 transcription factors that control fibrosis by promoting gene expression. However,
the importance of TGF-β–Smad2/3 signaling in fibroblast-mediated cardiac fibrosis has not been directly evaluated in
vivo. Here, we examined pressure overload–induced cardiac fibrosis in fibroblast- and myofibroblast-specific inducible
Cre-expressing mouse lines with selective deletion of the TGF-β receptors Tgfbr1/2, Smad2, or Smad3. Fibroblastspecific deletion of Tgfbr1/2 or Smad3, but not Smad2, markedly reduced the pressure overload–induced fibrotic
response as well as fibrosis mediated by a heart-specific, latency-resistant TGF-β mutant transgene. Interestingly, cardiac
fibroblast–specific deletion of Tgfbr1/2, but not Smad2/3, attenuated the cardiac hypertrophic response to pressure
overload stimulation. Mechanistically, loss of Smad2/3 from tissue-resident fibroblasts attenuated injury-induced cellular
expansion within the heart and the expression of fibrosis-mediating genes. Deletion of Smad2/3 or Tgfbr1/2 from cardiac
fibroblasts similarly inhibited the gene program for fibrosis and extracellular matrix remodeling, although deletion of
Tgfbr1/2 uniquely altered expression of an array of regulatory genes involved in cardiomyocyte homeostasis and disease
compensation. These findings implicate TGF-β–Smad2/3 signaling in activated tissue-resident cardiac fibroblasts as
principal mediators of the fibrotic response.
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Fibroblast-specific TGF-β–Smad2/3 signaling
underlies cardiac fibrosis
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Allendale, Michigan, USA. 3Department of Molecular Biology and Genetics, The Johns Hopkins University School of Medicine, Baltimore, Maryland, USA. 4Howard Hughes Medical Institute,
Cincinnati Children’s Hospital Medical Center, Cincinnati, Ohio, USA.

The master cytokine TGF-β mediates tissue fibrosis associated with inflammation and tissue injury. TGF-β induces
fibroblast activation and differentiation into myofibroblasts that secrete extracellular matrix proteins. Canonical TGF-β
signaling mobilizes Smad2 and Smad3 transcription factors that control fibrosis by promoting gene expression. However, the
importance of TGF-β–Smad2/3 signaling in fibroblast-mediated cardiac fibrosis has not been directly evaluated in vivo. Here,
we examined pressure overload–induced cardiac fibrosis in fibroblast- and myofibroblast-specific inducible Cre-expressing
mouse lines with selective deletion of the TGF-β receptors Tgfbr1/2, Smad2, or Smad3. Fibroblast-specific deletion of Tgfbr1/2
or Smad3, but not Smad2, markedly reduced the pressure overload–induced fibrotic response as well as fibrosis mediated
by a heart-specific, latency-resistant TGF-β mutant transgene. Interestingly, cardiac fibroblast–specific deletion of Tgfbr1/2,
but not Smad2/3, attenuated the cardiac hypertrophic response to pressure overload stimulation. Mechanistically, loss of
Smad2/3 from tissue-resident fibroblasts attenuated injury-induced cellular expansion within the heart and the expression
of fibrosis-mediating genes. Deletion of Smad2/3 or Tgfbr1/2 from cardiac fibroblasts similarly inhibited the gene program
for fibrosis and extracellular matrix remodeling, although deletion of Tgfbr1/2 uniquely altered expression of an array of
regulatory genes involved in cardiomyocyte homeostasis and disease compensation. These findings implicate TGF-β–
Smad2/3 signaling in activated tissue-resident cardiac fibroblasts as principal mediators of the fibrotic response.

Introduction

Heart failure is an increasingly prevalent disease characterized
by reduced cardiac output resulting from a progressive loss of
cardiomyocytes, ventricular chamber remodeling, and accumulation of interstitial fibrosis (1). Excessive deposition of extracellular matrix (ECM) in heart failure directly restricts normal
ventricular function by reducing wall compliance; it also reduces
diffusion efficiency, promotes arrhythmia, and possibly limits
regenerative efforts of cardiomyocytes (2–4). Progressive cardiac fibrosis in heart failure is predominantly mediated by the
tissue-resident cardiac fibroblast, which becomes activated and
then differentiated into a cell type referred to as the myofibroblast
(5, 6). Activation of fibroblasts within the heart is mediated by
inflammatory cytokines, neuroendocrine agonists, stretch of the
ventricular wall such as with pressure overload, or following myocardial infarction (MI) injury. In addition to producing and secreting abundant ECM material, myofibroblasts acquire contractile
activity through induction of genes such as Acta2 (α-smooth muscle actin [αSMA]), which allows these cells to physically remodel
the ECM or scar after MI (7, 8). While the physiologic function
of myofibroblasts is generally beneficial, such as during acute
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wound healing, sustained activation and continued generation of
these cells likely underlie inappropriate developmental remodeling and a wide range of adult fibrotic diseases (9–11). Thus, inhibition of myofibroblast conversion or their activity would be an
attractive therapeutic approach in adult fibrotic disease states,
including heart failure (12–14).
TGF-β is considered a “master” cytokine/growth factor produced within injured or diseased tissues, where it activates fibroblasts and facilitates ECM production (15, 16). TGF-β binds a heterodimeric receptor in the plasma membrane consisting of the
TGF-β type I and type II half-receptors, which together induce
phosphorylation of Smad2 and Smad3 transcription factors in
mediating canonical signaling. Phosphorylated Smad2 and Smad3
interact with Smad4 in the cytoplasm, where together they translocate to the nucleus to induce gene transcription (17). Activation
of the TGF-β type I and II receptors also initiates noncanonical signaling that results in the activation of the MAPK cascade, which
culminates in p38, JNK1/2, and ERK1/2 signaling (17).
Global Smad2–/– mice are embryonic lethal (18), whereas
Smad3 –/– mice are viable and hence have been examined for alterations in the fibrotic response (8, 19–22). For example, Smad3
underlies the proper induction of TGF-β–responsive genes, such
as Acta2, Col1a1, Col3a1, Fn, and Ctgf (20). Additionally, mice
lacking Smad3 were protected from chemical-induced fibrosis
in the kidney (23), fibrosis of the eye (24), and angiotensin II–
induced fibrosis of the vasculature (25). With respect to cardiac
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Figure 1. Canonical TGF-β signaling mediates
myofibroblast transformation in vitro. (A)
Western blot showing the expression levels of
Smad2, Smad3, Tgfbr2, and Cre in skin fibroblasts 72 hours after infection with Adβ-gal and
AdCre. (B) Representative immunofluorescent
images of cells infected with Adβ-gal control
or AdCre to delete Smad2/3 in skin fibroblasts
from Smad2/3fl/fl mice. αSMA+ stress fibers are
shown in green. Cells were treated with vehicle
or 10 ng/ml of TGF-β for 24 hours. Scale bars:
10 μm. (C) Quantitation of the experiment
shown in B except that additional genotypes of
primary skin fibroblasts were used as indicated.
Data are shown as ± SEM and are from 3 separate experiments. *P < 0.01 versus Adβ-gal.
P values were calculated by 1-way ANOVA with
post hoc Tukey’s HSD. (D and E) Pictures and
quantification of collagen gel matrix contraction
in culture dishes in Smad2-, Smad3-, Smad2/3-,
and Tgfbr1/2-loxP–targeted cardiac fibroblasts
infected with Adβ-gal or AdCre for 72 hours,
then treated with 10 ng/ml of TGF-β for 24
hours. Adβ-gal–infected cells without TGF-β
treatment showed no contraction in any of the
genotypes at baseline (not shown). Data are
shown as ± SEM and are from 3 separate experiments. *P < 0.01 versus WT Adβ-gal +TGF-β.
P values were calculated with 1-way ANOVA with
post hoc Tukey’s HSD. The wells in D are
28 mm across.

studies, global Smad3 –/– mice showed significantly greater lethality after pressure overload stimulation, although surviving mice
showed a 60% reduction in total ventricular fibrosis, with no difference in the degree of cardiac hypertrophy induction compared
with controls (19). In a separate study, Smad3 –/– mice were also
shown to have reduced fibrosis in the remote myocardium after
MI injury, although scar size was unaffected and total fibroblast
content was increased in these injured hearts (26). One limitation
of these past studies is a lack of cell-type specificity in attributing
how a global deletion of Smad3 might specifically affect the fibrotic
response in the heart. Indeed, cardiomyocyte-specific deletion
of Tgfbr2 from the hearts of mice blocked maladaptive responses
to pressure overload stimulation, inhibiting myocyte and interstitial Smad signaling and fibrosis (27). Thus, the cardiomyocyte

itself clearly plays a role in TGF-β–Smad2/3 signaling and fibrosis in the diseased heart. Here we utilized 2 recently developed
fibroblast-specific inducible Cre-expressing mouse lines to selectively delete Tgfbr1 and Tgfbr2 versus Smad2 and Smad3 to examine how canonical signaling at the level of the fibroblast underlies
fibrosis and disease responsiveness of the heart.

Results

Canonical TGF-β effectors Smad2/3 promote myofibroblast differentiation. To examine the possible differential role between Smad2
and Smad3 as mediators of TGF-β receptor signaling, we generated primary skin fibroblasts from mice with loxP site (fl) targeted
alleles for Smad2, Smad3, and Smad2/3 and compared them with
fibroblasts conditionally targeted within the Tgfbr1 and Tgfbr2 loci.
jci.org   Volume 127   Number 10   October 2017
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Figure 2. Generation of fibroblast-specific canonical TGF-β–deleted mice.
(A) Schematic representation of different mouse lines used, including
the Postn genetic locus containing a tamoxifen-regulated MCM cDNA
cassette inserted into exon 1 (E1), which was crossed with Smad2- and/
or Smad3-loxP–containing gene-targeted lines, along with the Rosa26
reporter allele(R26EGFP). The mouse chromosome associated with each
allele is shown. (B) Experimental scheme whereby mice were subjected to
TAC injury or sham procedure for 4 and 12 weeks. Mice were fed tamoxifen diet 48 hours before surgery and then maintained on tamoxifen until
harvesting. (C) Representative histological section showing EGFP-labeled
interstitial cells in hearts of PostnMCM/+ R26EGFP/+ mice after 4 weeks of
TAC injury (n = 4). Scale bar: 10 μm. (D) Western blot analysis for Smad2,
Smad3, and EGFP from 500,000 cells isolated from hearts of the 2 genotypes of mice shown. (E) Western blot for Tgfbr2 in total heart mesenchymal cells lacking myocytes, CD31, and CD45 cells and conditionally targeted
for Tgfbr1/2-loxP with PostnMCM in cardiac-activated fibroblasts after TAC
stimulation.

These primary skin fibroblasts were infected with a Cre-expressing
adenovirus (AdCre) and compared with a control β-gal–expressing
(Adβ-gal–expressing) adenovirus (Figure 1A). Western blotting of
protein extracts from these primary fibroblasts 72 hours after re
combinant adenoviral infection showed efficient deletion of Smad2
and Smad3 protein from Smad2/3fl/fl double-homozygous cells with
AdCre and efficient deletion of Tgfbr2 in Tgfbr1/2fl/fl homozygous
cells (Figure 1A). Control and AdCre-infected Smad2fl/fl, Smad3fl/fl,
and Smad2/3fl/fl primary fibroblasts were stimulated with TGF-β and
assayed for differentiation into myofibroblasts, as marked by αSMA
expression. The data show that 70%–80% of the Adβ-gal–infected
Smad2fl/fl, Smad3fl/fl, and Smad2/3fl/fl or Tgfbr1/2fl/fl fibroblasts became
αSMA positive with TGF-β stimulation, while AdCre infection
blocked this induction with deletion of Smad3, Smad2/3, or Tgfbr1/2,
but not Smad2 (Figure 1, B and C).
Targeted primary cardiac fibroblasts were also seeded into
Matrigel for contraction assays as a more specific assessment of
TGF-β–induced myofibroblast formation with contractile activity (Figure 1D). Here, we observed robust gel contraction in WT
fibroblasts (not shown) and all the genotypes of primary cardiac
fibroblasts tested that were infected with Adβ-gal (Figure 1, D and
E). AdCre-infected Smad2fl/fl fibroblasts also showed full gel contraction comparable to that of WT fibroblasts with TGF-β stimulation (Figure 1, D and E). However, AdCre infection of Smad3fl/fl,
Smad2/3fl/fl, and Tgfbr1/2fl/fl fibroblasts showed inhibition in TGF-β–
induced gel contraction (Figure 1, D and E). These results indicate
that the 2 central TGF-β receptors and Smad3 are critical mediators
of myofibroblast differentiation and function in vitro with TGF-β
stimulation, but that Smad2 was not necessary for this response.
3772
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Activated fibroblast-specific Smad2-, Smad3-, and Smad2/3deleted mice. Previous genetic-based studies designed to inhibit
TGF-β signaling in heart disease models have lacked selectivity
for the fibroblast (19, 26–28). Hence, here we used mice in which
the Postn genetic locus was targeted with a tamoxifen-inducible
MerCreMer (MCM) cDNA (29), and these mice were crossed with
Smad2fl/fl, Smad3fl/fl, Smad2/3fl/fl, and Tgfbr1/2fl/fl targeted mice (Figure 2A). We also introduced a single Rosa26-loxP-Stop-loxP-EGFP
(R26EGFP) reporter allele to allow irreversible tracking of all activated fibroblasts, as previously described (29). Importantly, periostin expression is specifically induced in essentially all activated
fibroblasts (myofibroblasts) of the heart with injury (30–32). Young
adult mice were subjected to cardiac pressure overload stimulation
by transverse aortic constriction (TAC) surgery over 4 to 12 weeks
in the presence of tamoxifen food so that the MCM protein could
mediate recombination in activated fibroblasts (Figure 2B). Indeed,
immunohistochemistry in PostnMCM/+ R26EGFP/+ mice over 4 weeks
of TAC in the presence of tamoxifen showed EGFP expression in
activated fibroblasts throughout the heart (Figure 2C), as previously characterized in detail (29). In an identical experiment in mice
that also contained the Smad2/3fl/fl alleles, EGFP-labeled cells were
subjected to FACS and pooled for Western blotting to assess the
degree to which Smad2 and Smad3 proteins were deleted from activated cardiac fibroblasts after 4 weeks of TAC. The results showed
almost complete absence of these 2 proteins compared with
similarly sorted control fibroblasts that were not targeted for
the Smad2/3 alleles (Figure 2D). A similar strategy in Tgfbr1/2fl/fl
PostnMCM/+ mice was performed in which cardiomyocyte-free total
mesenchymal cells were negatively sorted to remove CD31- and
CD45-expressing cells and protein extracts generated, which
showed an approximate 80% deletion of Tgfbr2 protein (Figure
2E). These results indicate that the PostnMCM allele effectively deletes
loxP-targeted genes from activated fibroblasts from the heart.
Role of Smad2, Smad3, and Tgfbr1/2 in fibroblast-dependent cardiac fibrosis with pressure overload. TAC was performed in young
adult mice for 4 or 12 weeks to assess pressure overload–induced
cardiac fibrosis in which Smad2, Smad3, Smad2/3, or Tgfbr1/2 was
specifically deleted from activated fibroblasts (Figure 2B). Levels of
fibrosis and collagen deposition in each genotype were assessed by
Masson’s trichrome staining of cardiac histological sections (Figure
3, A and B, and Supplemental Figure 1A, and Supplemental Figure 2;
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Figure 3. Fibroblast-specific deletion of canonical TGF-β signaling reduces myocardial fibrosis in mice. (A and B) Masson’s trichrome–stained histological pictures and quantitation of the area of fibrosis (blue) in hearts from the indicated genotypes of mice with PostnMCM/+ after 12 weeks of TAC injury
and tamoxifen treatment. Average fibrotic area ± SEM. n = 8–10 mice in each group. *P < 0.05 versus sham operated; #P < 0.05 versus PostnMCM/+ TAC at
4 or 12 weeks. P values were calculated by 1-way ANOVA with post hoc Tukey’s HSD. (C and D) Masson’s trichrome–stained histological photographs and
quantification of the area of fibrosis in hearts from the indicated mice crossed with Tcf21MCM/+ after 4 weeks of TAC injury and tamoxifen treatment. Average fibrotic area ± SEM. n = 6–9 mice in each group, *P < 0.05 versus sham operated; #P < 0.05 versus Tcf21MCM/+ TAC at 4 weeks. P values were calculated
by 1-way ANOVA with post hoc Tukey’s HSD. (E and F) Masson’s trichrome–stained histological photographs and quantification of the area of fibrosis in
αMHCMCM/+ and cardiomyocyte-specific deletion of Smad2/3 from hearts after 12 weeks of TAC injury. Mice were injected 5 times with 100 μl of 0.5 mg/ml
of tamoxifen 15 days before injury. Average fibrotic area ± SEM. n = 7–9 mice in each group. *P < 0.05 versus sham operated. P values were calculated using
1-way ANOVA with post hoc Tukey’s HSD. Scale bars: 150 μm.

jci.org   Volume 127   Number 10   October 2017
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Figure 4. Fibroblast-specific Smad2/3 deletion alters myofibroblast activity in vivo. (A) Experimental scheme whereby mice were subjected to TAC
for 4 weeks. Mice were fed tamoxifen-laden chow 48 hours before surgery and then until harvesting. (B and C) Representative immunostaining images
and quantitation for EGFP+ cellular expression (green) and costaining for αSMA (red) and DAPI (blue) in isolated cardiac interstitial cells from the
indicated genotypes of mice that were cultured for 96 hours in low serum medium. The white arrows indicate EGFP+ cells and the yellow arrow shows
EGFP– cells that are αSMA+ (n = 4). *P < 0.05 versus PostnMCM/+ R26EGFP/+ cells. P values were calculated with Student’s t test. Scale bars: 10 μm. (D and
E) Representative immunohistochemistry cryosections and quantitation of EGFP-labeled (green) interstitial cells along with αSMA (red) staining from
hearts of the indicated genotypes of mice after 4 weeks of TAC. The white arrows show EGFP+ cells that are also αSMA+ in each of the 2 genotypes of
mice, although in the Smad2/3-deleted hearts, most of the EGFP+ fibroblasts are deficient in αSMA expression (n = 4 mice in each group). *P < 0.05
versus PostnMCM R26EGFP hearts. P values were calculated with Student’s t test. Scale bars: 10 μm. Additional images of immunohistochemistry as
shown in D are shown in Supplemental Figure 5.

supplemental material available online with this article; https://doi.
org/10.1172/JCI94753DS1). The data show that deletion of Smad3,
Smad2/3, or Tgfbr1/2, but not Smad2, significantly attenuated the
cardiac fibrotic response to pressure overload following 4 and 12
weeks of TAC stimulation (Figure 3, A and B). Because Smad2 and
Smad3 are transcription factors that have been implicated in directly
mediating expression of myofibroblast genes (17, 20, 33–38), we
assessed mRNA levels of endogenous Postn, Col1a1, and Col3a1
from primary cardiac fibroblasts treated with TGF-β in culture. The
data show a generalized and significant reduction in expression
of these 3 activated fibroblast marker genes in both Smad3- and
Smad2/3-deleted fibroblasts, but not with deletion of Smad2 (Supplemental Figure 3, A–C). These data indicate that deleting canon3774
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ical TGF-β signaling constituents from newly activated fibroblasts
significantly reduces the cardiac fibrotic response, although Smad2
appeared to be fully compensated by the remaining Smad3 gene.
In parallel, echocardiography at 4 and 12 weeks after TAC was
employed to determine whether loss of Smad2/3 or Tgfbr1/2 signaling from activated fibroblasts affected heart function and/or the
hypertrophic response. Twelve weeks of TAC stimulation resulted
in a significant reduction in ventricular fractional shortening in
control mice (controls consisted of PostnMCM/+ alone or Smad2/3fl/fl
alone) versus sham-operated mice (Supplemental Figure 4A).
Deletion of Smad2, Smad3, or Smad2/3 from activated fibroblasts
resulted in the same significant reduction in ventricular fractional
shortening as seen in the controls after TAC, although deletion of
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Figure 5. Fibroblast-specific Smad2/3
deletion reduces the number of activated
myofibroblasts in vivo. (A) Experimental
schematic whereby mice were subjected
to TAC injury for 7 days. Mice were fed
tamoxifen-laden chow 48 hours before
surgery and then until harvesting. EdU
was injected into mice 24 hours and 4
hours before harvest. (B and C) Representative flow cytometry plots of isolated
EGFP+ interstitial cells (rightward scatter)
from hearts of the indicated genotypes of
mice. (D) The ratio of total GFP+ activated
fibroblasts normalized to CD31+ cells
from the heart taken from the indicated
genotypes of mice after 1 or 4 weeks of
TAC. Error bars represent SEM. n = 3 mice
in each group. *P < 0.05 versus PostnMCM/+
R26EGFP/+. P values were calculated with
Student’s t test. (E and F) Representative immunohistological images and
quantitation of the percentage of EGFP+
interstitial cells costained for EdU (white)
according to the schematic in A. DAPI was
used to show nuclei (blue). n = 3 mice in
each group. *P < 0.05 versus PostnMCM/+
R26EGFP/+. P values were calculated with
Student’s t test. Scale bars: 50 μm. (G)
Quantitation of CD31-positive cells that
were also EdU positive in heart histological sections from mice subjected to TAC of
the indicated genotypes. Representative
images of the CD31-positive cells with
EdU staining along with GFP-positive
fibroblasts from histological heart sections are shown in Supplemental Figure 6.

Tgfbr1/2 significantly protected from this profile of reduced ventricular performance (Supplemental Figure 4A). Similarly, Smad2,
Smad3, and Smad2/3 fibroblast–targeted mice showed a similar
degree of cardiac hypertrophy following 12 weeks of TAC as controls, yet deletion of Tgfbr1/2 with PostnMCM/+ resulted in significantly
less cardiac hypertrophy (Supplemental Figure 4B, see Discussion).
In support of these data, histological analysis of cardiomyocyte cell
surface areas in hearts of these same mice showed significantly
less hypertrophy with Tgfbr1/2 deletion after 4 weeks of TAC compared with controls or Smad2/3 deletion after TAC, while Smad2/3
heart–specific deleted mice showed the same level of hypertrophy
as WT mice (control sham = 281 ± 10 μm2, control TAC = 483 ± 12
μm2, Smad2/3 deleted = 494 ± 12 μm2, Tgfbr1/2 deleted = 309 ± 8
μm2; P < 0.05 versus control TAC, n = 4 mice in each group). We also
performed a more advanced echocardiographic procedure with
strain analysis 4 weeks after TAC. The data showed a trend toward
reduced longitudinal left ventricular wall strain in Smad2/3 doubledeleted mice compared with control or Tgfbr1/2-KO mice after
TAC (Supplemental Figure 4C). Interestingly, diastolic function
measured indirectly by pulse-wave and tissue Doppler echocardiography indicated a lower E/e′ ratio (where E indicates E wave and e′
indicates peak tissue velocity) in Tgfbr1/2 double-deleted mice after
TAC compared with control or Smad2/3 double-deleted mice, suggestive of preserved diastolic function (Supplemental Figure 4D).

One possible limitation with the PostnMCM allele is that it requires
fibroblast activation before the loxP-targeted gene under investigation would be deleted. Hence, Smad2/3 would likely become partially induced before deletion occurs with the PostnMCM/+ allele. To
deal with this hypothetical situation, we employed an independent
tamoxifen-inducible Cre-expressing gene-targeted mouse line
in which the transcription factor 21 (Tcf21) allele is targeted with
the MCM cDNA (Tcf21MCM). We and others have shown that the
Tcf21MCM/+ allele is expressed in essentially all tissue-resident fibroblasts in the uninjured heart, but no other cell types, and that these
cells beget the activated fibroblasts (29, 39). Here, we used 4 weeks
of TAC with tamoxifen treatment in Tcf21MCM/+ mice crossed with
Smad3fl/fl, Smad2/3fl/fl, and Tgfbr1/2fl/fl mice. We again observed the
same significant reduction in cardiac fibrosis as with the PostnMCM/+
allele crossed with these same loxP-targeted genes (Figure 3, C and
D, and Supplemental Figure 1B). Hence, deletion of Smad2/3 with the
Tcf21MCM allele from cardiac fibroblasts before they become activated is similarly effective in attenuating the disease-dependent fibrotic
response, as observed with the slightly later induced PostnMCM allele.
Deletion of Tgfbr1 or Tgfbr2 from cardiomyocytes of the heart
was shown to protect from cardiac fibrosis and functional decompensation with remodeling following pressure overload (27). Here,
we deleted Smad2/3 from the adult heart using the α-myosin heavy
chain (αMHC) MCM-containing transgene (40) to determine
jci.org   Volume 127   Number 10   October 2017
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Figure 6. Fibroblast-specific deletion of Smad2/3 reduces TGF-β–
induced myocardial fibrosis. (A) Schematic representation of PostnMCM
mice crossed to Smad2- and/or Smad3-loxP mice in conjunction with an
inducible heart-specific latency-escaping TGF-β mutant cDNA driven by a
cardiomyocyte-specific DTG system. (B) Representative histological heart
sections with GFP+ interstitial cells (white arrows) showing that the TGF-β
DTG effectively mediated Cre-dependent induction of PostnMCM/+activity,
facilitating R26EGFP recombination and expression, while deletion of
Smad2/3 reduced total EGFP+ cells. Hearts were harvested 4 weeks after
tamoxifen administration. n = 4 mice harvested. Scale bars: 10 μm. (C)
Experimental schematic whereby data shown in D and E were from mice
fed tamoxifen through 12 months of age. (D and E) Pictures of Masson’s
trichrome–stained cardiac histological sections and quantitation of the
area of fibrosis (blue staining) in the indicated genotypes of mice in the
presence of the TGF-β mutant transgenic system (DTG) for 12 months.
Data are shown as average fibrotic area ± SEM. n = 6–8 in each group.
*P < 0.05 versus PostnMCM/+; #P < 0.05 versus DTG PostnMCM/+. P values were
calculated by 1-way ANOVA with post hoc Tukey’s HSD. Scale bars: 150 μm.

whether canonical Smad2/3 signaling within cardiomyocytes might
similarly affect the cardiac fibrotic response with pressure overload.
However, unlike deletion of Smad2/3 from cardiac fibroblasts, as
presented above, deletion of Smad2/3 specifically from cardiomy3776
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ocytes of mice with 12 weeks of pressure overload showed no ability
to inhibit the fibrotic response compared with αMHCMCM controls
(Figure 3, E and F, and Supplemental Figure 1C). Thus, the ability of
Smad2/3 transcriptional activity to support disease-mediated cardiac fibrosis appears to be largely specific to the cardiac fibroblast.
Deletion of Smad2/3 compromises myofibroblasts in vivo. Deletion
of Smad2/3 from resting or activated fibroblasts in the hearts of
mice subjected to TAC substantially reduced the fibrotic response,
although the cellular basis for this reduction in fibrosis was unknown.
Here, we examined the fate of activated fibroblasts/myofibroblasts
in the heart following Smad2/3 deletion. PostnMCM/+ R26EGFP/+ mice
were used as a control versus the same genotype of mice that also
contained the Smad2/3fl/fl alleles, and young adults were subjected
to 4 weeks of TAC with tamoxifen chow administration (Figure
4A). We first removed hearts from these mice and isolated total
interstitial cells and cultured them as a mixed population (Figure
4B). Interestingly, we observed that approximately 90% of EGFP+
control cells replete with the Smad2/3 alleles became αSMA positive in culture yet nearly all the EGFP+ cells in the Smad2/3 targeted
interstitial cell pool were devoid of αSMA expression and lacked the
characteristic stress fibers of myofibroblasts (Figure 4, B and C). We
also performed direct analysis of EGFP+ versus αSMA-expressing
cells in the heart from the same 2 groups of mice after 4 weeks of
TAC (Figure 4D). The data show that 78% of EGFP+ Postn-traced
activated fibroblasts in the heart are also αSMA expressing when
Smad2/3 are present, while only 30% overlap was observed when
Smad2/3 are deleted from activated cardiac fibroblasts (Figure 4,
D and E, and Supplemental Figure 5). Indeed, most of the EGFP+
fibroblasts in the hearts of PostnMCM/+ Smad2/3fl/fl mice after 4 weeks
of TAC lacked αSMA expression (Figure 4D).
To analyze fibroblast proliferation rates, mice of the genotype
PostnMCM/+ Smad2/3fl/fl R26EGFP/+ were compared with controls of
the genotype PostnMCM/+ R26EGFP/+ and subjected to 1 or 4 weeks of
TAC stimulation with tamoxifen administration to trace fibroblasts
(Figure 5A). Importantly, at the 1-week time point, 5-ethynyl-2′deoxyuridine (EdU) was given in the last 24 hours before sacrifice so
that proliferation rates could be directly assessed (Figure 5A). Hearts
were then collected from these 2 groups of mice and digested and
total EGFP+ cells counted and normalized to CD31+ (Supplemental
Figure 6) or Erg1+ (data not shown) endothelial cells as an approxi-
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Figure 7. Smad2/3 deletion in activated fibroblasts reduces fibroblast and ECM-related gene expression. (A) Gene expression cluster analysis showed a
profile of altered ECM and fibrosis-related gene expression in EGFP+ fibroblasts obtained from hearts of Smad2/3-activated fibroblast-deleted mice versus
control WT hearts, isolated 4 weeks after TAC injury. (B) Quantification of selected mRNAs in Smad2/3-deleted EGFP+-activated fibroblasts from hearts
of Smad2/3 PostnMCM/+ R26EGFP/+ allele–containing mice. (C) Gene expression cluster analysis shows a profile of altered ECM- and fibrosis-related gene
expression in EGFP+ fibroblasts obtained from hearts of Tgfbr1/2 fibroblast–deleted mice versus control WT hearts, isolated 4 weeks after TAC injury. (D)
Quantification of selected mRNAs in Tgfbr1/2-deleted EGFP+ fibroblasts from hearts of Tgfbr1/2 Tcf21MCM/+ R26EGFP/+ allele–containing mice. The white bars in
D represent genes altered in expression compared with those with deletion of Smad2/3.

mation of activated fibroblast expansion and endothelial cell proliferation with EdU administration. While endothelial cells do expand
with pressure overload stimulation, it is generally less than 30% (41,
42), and this effect was the same between our 2 experimental groups
with or without Smad2/3 in activated cardiac fibroblasts (Figure 5G
and Supplemental Figure 6). The data show a dramatic reduction in
total activated EGFP+ fibroblasts in the hearts of Smad2/3-deleted
mice after 4 weeks of TAC compared with control mice replete with
Smad2/3 in their activated fibroblasts (Figure 5, B–D). Even with 1
week of TAC, there was a significant reduction in EGFP+ activated
fibroblasts when Smad2/3 were deleted from these cells (Figure 5D).
Histological sections were also directly quantified for EGFP+
fibroblasts or immunostained for endothelial cells that were pos-

itive or negative for EdU incorporation (Figure 5, E–G, and Supplemental Figure 6). The data show that over 24 hours of EdU
exposure, 13% of EGFP+ activated fibroblasts incorporated EdU,
suggesting the cells were actively proliferating, while approximately 1% of the Smad2/3-deleted EGFP+ activated fibroblasts
incorporated EdU (Figure 5, E and F). As a control, there was
equivalent proliferation of endogenous endothelial cells between
the 2 groups with TAC stimulation to the heart (Figure 5G). Also
as an important control, loss of Smad2/3 or Tgfbr1/2 from primary
skin fibroblasts did not differentially affect their sensitivity to cell
death through apoptosis with staurosporine in culture compared
with WT (Supplemental Figure 7). Thus, loss of Smad2/3 from
disease-activated fibroblasts in the heart compromises their difjci.org   Volume 127   Number 10   October 2017
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ferentiation and proliferation, but not cell death, suggesting a cellular mechanism for the observed reduction in fibrosis in mice in
which Smad2/3 are deleted from cardiac fibroblasts.
Smad2/3 deletion from fibroblasts compromises TGF-β–induced
fibrosis in the heart. To confirm and extend our observations to
this point, a cardiac-specific, latency-escaping mutant TGF-β–
expressing (TGF-β1Cys223,225Ser) transgene was used, which we previously showed induces interstitial cardiac fibrosis (43). Double transgenic (DTG) mice with this bigenic inducible system were crossed
with Smad2fl/fl, Smad3fl/fl, or Smad2/3fl/fl mice (Figure 6A, no doxycycline was given so that the transgene was always active). The R26EGFP
allele was also present and tamoxifen was administered beginning
at 4 weeks of age so that fibroblasts could be visualized and directly
assessed in vivo. The data show that EGFP+ cells were observed in
the heart at 2 months of age, suggesting that the TGF-β transgene
induced PostnMCM activity in activated fibroblasts (Figure 6B), while
control mice without the TGF-β DTG system showed essentially
no EGFP+ cells in the ventricles at 2 months (data not shown). We
observed substantially fewer EGFP+ traced fibroblasts in the hearts
of TGF-β DTG mice in the absence of Smad2/3 (Figure 6B).
We next performed a chronic fibrosis study in which TGF-β
DTG mice were put on tamoxifen (without doxycycline, for full
induction) at 4 weeks of age and followed for 1 year before the
hearts were harvested (Figure 6C). Masson’s trichrome analysis
showed that TGF-β DTG mice with the PostnMCM/+ allele had fibrosis
in their hearts by 12 months of age compared with hearts from WT
or PostnMCM/+ mice lacking the TGF-β transgene (Figure 6, D and E,
and Supplemental Figure 1D). However, deletion of Smad3 alone
or Smad2/3 from activated fibroblasts of these same TGF-β DTG
PostnMCM/+ mice showed a significant reduction in cardiac fibrosis
compared with the TGF-β DTG PostnMCM/+ control mice (Figure 6,
D and E, and Supplemental Figure 1D). As observed with TAC stimulation, deletion of Smad2 was not effective in reducing the cardiac
fibrotic response, as these mice showed significant fibrosis that was
not statistically different from that in TGF-β DTG PostnMCM/+ control
mice (Figure 6E). Hence, Smad3 appears to be the dominant effector of TGF-β–induced cardiac fibrosis in the mouse heart, while
Smad2 appears to be fully compensated by the presence of Smad3.
Gene expression alterations in Smad2/3- versus Tgfbr1/2-deficient
fibroblasts. To gain further insight into the molecular basis for
Smad2/3-dependent regulation of fibroblast activity and fibrosis,
global RNA-sequencing (RNA-Seq) profiling was performed. EGFP+
cells were obtained by FACS from hearts of PostnMCM/+ R26EGFP/+ versus PostnMCM/+ Smad2/3fl/fl R26EGFP/+ mice 4 weeks after TAC injury.
Bioinformatics analysis of the data showed a gene expression signature in which many of the top categories of gene pathways were
related to the activity or function of myo/fibroblasts or the ECM
(Figure 7A). For example, the expression of direct ECM mRNAs
Col1a1, Col1a2, Col3a1, Fn1, Fbn1, and Tnc in EGFP+ fibroblasts
showed significantly reduced levels in the absence of Smad2/3. Also
downregulated were the ECM-modifying genes Loxl2, Adam12,
Adam30, and Sparc along with the cell-adhesion genes Itga2, Itga8,
and Itgb3 (Figure 7B). Key proliferation genes such as Mki67 and
Cdk6 were significantly downregulated in Smad2/3-deleted fibroblasts as well (Figure 7B), which is consistent with the known profile
of compromised proliferation of these cells observed in vivo after
injury (Figure 5). No significant changes were observed between
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the 2 genotypes of fibroblasts analyzed in the relative expression of
the global fibroblast identity markers Tcf21, Pdgfra, and Vimr or in a
housekeeping gene such as Actb (Figure 7B).
EGFP+ cells were also obtained from hearts of Tcf21MCM/+
R26EGFP/+ versus Tcf21MCM/+ Tgfbr1/2fl/fl R26EGFP/+ mice 4 weeks after
TAC injury. Bioinformatics analysis of these data showed a gene
expression signature similar to that found with Smad2/3 deletion in
that most of the top categories of gene pathways were related to the
activity or function of fibroblasts and the ECM (Figure 7C). Hence,
the overwhelming effect associated with deletion of the 2 TGF-β
receptors from cardiac fibroblasts with pressure overload stimulation is an alteration in fibrosis and ECM-associated gene expression
(Figure 7, C and D). As with Smad2/3 deletion, we observed downregulation of a large array of fibrosis, adhesion, and ECM genes such
as Col1a1, Col3a1, Col4a3, Col11a1, Fn1, Fbn1, Sparc, Itga2, Itga8, Eln,
Postn, and Adams (Figure 7D). However, loss of Tgfbr1/2 from cardiac fibroblasts also substantially altered expression of genes not
observed with deletion of Smad2/3, and many of these had interesting regulatory implications, such as a decrease in Tgfb2, Tgfbi, and
Tgfb3 (Figure 7D). Also of interest, Fgf16 and Ptn are known protective factors in the heart (44–46) that were each substantially downregulated with loss of Tgfbr1/2 (Figure 7D). Other genes implicated
in cardiac homeostasis, such as Ahsg, Fetub, Gpx1, Gpx3, Serpina3n,
Ptn, Timp1, and Timp4, were also uniquely changed in the absence
of Tgfbr1/2, but not with Smad2/3 deletion (Figure 7D). Some of
these genes could contribute to the differential cardiac compensatory and hypertrophy effects shown in Supplemental Figure 4.

Discussion

Global TGF-β activity is upregulated in diseased hearts, where
one of its primary actions is directed at the resident fibroblasts
to alter the fibrotic response and ventricular remodeling (47,
48). However, all previous studies that manipulated TGF-β
signaling in the heart either used mice with global Smad3 deletion, which results in loss of SMAD3 protein in all cells (19, 26),
mice with cardiac-specific deletion of Tgfbr1 or Tgfbr2, or mice
treated with systemically acting drugs or blocking antibodies
that do not distinguish cell type of action (27, 28, 49). In this
study, we uniquely interrogated the cardiac fibroblast as a putative mediator of heart disease in vivo. Our results indicate that
the tissue-resident cardiac fibroblast is primarily responsible
for mounting a fibrotic response with pressure overload stimulation. These results indicate that Smad2/3 are critical in the
induction and maintenance of activated fibroblast activity and
productive fibrosis in the heart in response to pressure overload
or the TGF-β ligand itself. In comparison, deletion of Smad2/3
specifically from cardiomyocytes was ineffective in altering the
pressure overload cardiac fibrotic response.
Another interesting observation was that deletion of Smad2
from activated fibroblasts did not diminish their activation profile,
ability to induce αSMA, ability to contract a collagen gel, or ability to
mediate a fibrotic response in vivo. In contrast, deletion of Smad3
from activated fibroblasts compromised the differentiated function
and activity of these cells in culture and in vivo. While Smad2–/– mice
have not been extensively studied given their embryonic lethal phenotype, our results with the conditional loxP-targeting approach
suggest that this transcription factor is not central to the fibrotic
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response from the standpoint of the activated fibroblast. However,
our results in Smad3-loxP–targeted mice in which this gene was only
deleted from activated fibroblasts were consistent with data from
global Smad3–/– mice in which the cardiac fibrotic response was
reduced following pressure overload or MI injury (19, 20, 26).
With respect to Smad3 being more important than Smad2 in
mediating fibroblast activation and fibrosis in vivo, one simple
explanation could be that Smad3 is more highly expressed in cardiac fibroblasts, although this does not appear to be the case (Figure 2D). Indeed, others have also reported that Smad3 appears to
function dominantly over Smad2 in other systems. For example,
Smad3 dominates over Smad2 in regulating TGF-β–dependent
chondrogenic differentiation (50). Moreover, Smad3, but not
Smad2, is part of a transcriptional regulatory complex with histone deacetylase-1 (HDAC1) in binding to the PPARγ promoter
in mouse cardiac fibroblasts (51). In hepatic stellate cells (fibroblasts), knockdown of Smad3 reduced TGF-β–induced type 1a
collagen expression while knockdown of Smad2 increased its
expression and Smad2 overexpression reduced type 1a collagen
expression (52). Finally, transcriptional profiling in Hep3B cells
showed that knockdown of Smad2 versus Smad3 resulted in 190
genes being differentially controlled, and again, Smad3 was dominant over Smad2 in how TGF-β affected these cells (53).
Loss of Smad2/3 rendered newly activated fibroblasts in the
heart less proliferative and compromised in their differentiated
function and ability to express fibrosis-mediating genes. A wealth
of past literature suggests that Smad2/3 directly bind to the promoters of fibrosis and myofibroblast-dependent genes to modulate their expression characteristics (17, 20, 33–38, 52, 53). Here,
we observed that loss of Smad2/3 from activated cardiac fibroblasts rendered them unable to induce or even maintain normal
baseline expression of fibrosis-dependent signature genes, while
loss of Smad2 was of little effect. Such a defect in fibroblast gene
expression would have obvious functional implications on newly
activated fibroblasts in vivo, hence explaining the observed phenotype in mice with Smad2/3 deletion mediated by the PostnMCM
allele in response to cardiac pressure overload. Fibroblast proliferation was also compromised in pressure-overloaded hearts when
Smad2/3 were deleted from activated fibroblasts, again partially
explaining why the fibrotic response in these hearts was attenuated.
While deletion of Smad2/3 from fibroblasts reduced cardiac
fibrosis during 12 weeks of pressure overload stimulation, it did
not alter the ultimate decompensation of these hearts as assessed
by echocardiography (fractional shortening) or the hypertrophy
of these hearts by gravimetric analysis. In dramatic contrast,
deletion of Tgfbr1/2 genes from activated fibroblasts of pressureoverloaded hearts similarly reduced expression of fibrosismediating genes, but it uniquely benefitted the hearts of these
mice such that they did not show a reduction in left ventricular fractional shortening, and the degree of cardiac hypertrophy
was reduced compared with that of controls. On the surface, this
observation might simply reflect the fact that Tgfbr1/2 signaling is
upstream of both canonical (Smad2/3) and noncanonical (MAPK)
TGF-β signaling. Canonical signaling through Smad2/3 could be
more dedicated to direct regulation of fibrosis-mediating genes,
while noncanonical signaling such as through p38α MAPK, which
we recently showed is also critical for fibrosis (54), might have

additional complexity in augmenting expression of genes that
directly control other regulatory pathways in the heart that affect
hypertrophy or compensation with injury. Indeed, global mRNA
profiling of fibroblasts deleted for Tgfbr1/2 showed altered expression for an array of important cardiac regulatory genes that was
not observed with Smad2/3 deletion (Figure 7D). Any one of these
genes, or more likely, the entire profile of uniquely changed genes
could easily underlie the observed phenotypic differences in compensation and pressure overload–induced hypertrophy observed
between Tgfbr1/2 and Smad2/3 fibroblast–deleted mice.
The observations presented here suggest a bifurcation point in
attempting future therapeutic strategies aimed at TGF-β for affecting cardiac fibrosis with longstanding chronic disease states. The
ability to selectively block canonical signaling through Smad2/3
should reduce fibrosis itself without altering other growthdependent effects of TGF-β. Alternatively, blocking all upstream
noncanonical TGF-β signaling would similarly have an effect on
cardiac fibrosis, but could also be additionally protective to the
heart by reducing other maladaptive signaling effects. Indeed,
deletion of Mapk14 from activated fibroblasts of the heart reduced
fibrosis with MI injury or neuroendocrine agonists (54). Thus, targeting one aspect of TGF-β signaling as an antifibrotic approach
might circumvent the known ineffectualness associated with
drugs or antibodies that globally block TGF-β signaling (55).
Moreover, designing delivery methods to specifically target the
activated fibroblast might also provide selectivity that limits side
effects associated with total systemic TGF-β inhibition (55).

Methods

Mice. Mice containing a knockin of a MCM cDNA into either the Postn
or Tcf21 genomic loci were previously described (29, 39). αMHCMCM transgenic mice (40) and TGF-β tTA DTG transgenic mice
(56) were previously described. Tgfbr1/2-loxP–targeted mice were
previously described (27). Rosa26 reporter mice (R26EGFP) were previously described (57) and were purchased from the Jackson Laboratory (catalog 012429). LoxP-targeted Smad2/3 mice were recently
described as well (58). PCR genotyping used the primers Smad3 forward 5′-GTTTACTGGACTGAGGTTGGCTGTGGC-3′ and reverse
5′-GTACAGATTGGCCACTCCGGTCACTG-3′, which generated a
390-bp product recognizing loxP-targeted exons 2/3 and 287-bp WT
fragments. Smad2 genotyping primers 5′-ATAATGGGTCCCAGTAACACCGGAC-3′ and 5′-CTCAAACCTTACCAAGCCAAAGCAG-3′
generated a 400-bp product recognizing the loxP-containing site in
exon 2 and a 360-bp WT fragment. αMHC-MerCreMer mice received
i.p. injections with pharmaceutical grade tamoxifen (20 mg/kg body
weight) dissolved in 95% peanut oil/ 5% ethanol for 5 consecutive
days 15 days before the surgical procedure. Postn-MerCreMer mice
received continuous tamoxifen-citrate chow feeding (40 mg/kg body
weight, Envigo - TD.130860) 48hrs before a procedure and then until
the experiment was terminated. Tcf21-MerCreMer mice received 15
days of tamoxifen food before a procedure that continued until harvest. All strains of mice were in the C57BL/6 genetic background.
Animal procedures. Eight- to ten-week-old male mice of the relevant
genotypes were subjected to pressure overload by TAC surgery. A silk
ligature was tied around the aorta together with 26-gauge blunted needle between the origins of the right innominate and left common carotid
artery, after which the needle was removed to generate a defined conjci.org   Volume 127   Number 10   October 2017
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striction. A sham surgical procedure was identical, but without ligature
placement. Echocardiography was performed to assess ventricular geometry and function at 4 and 12 weeks after TAC. Echocardiography was performed in mice under 2% isoflurane inhalation anesthesia (until effect),
and measurements were performed using a Hewlett Packard 5500
instrument with a 15-MHz microprobe and recorded on M-mode in triplicate for each mouse and averaged. Doppler echocardiography was performed on mice subjected to TAC to measure pressure gradients across
the aortic constriction to verify the effectiveness of the TAC procedure.
For analysis of longitudinal strain and diastolic function by echocardiography, a Vevo 2100 instrument with 18–38 MHz transducer
(VisualSonics) was used as previously described (59). Longitudinal
B-mode loops of 300 frames each were analyzed using VevoLAB
speckle-based tracking (VisualSonics) to determine average longitudinal strain across the left ventricle. For indirect measurement of diastolic function, pulse-wave Doppler echocardiography was performed
across the mitral valve leaflets in an apical long-axis view to determine peak flow velocity (E wave). Tissue Doppler was performed in a
short-axis view at the level of the papillary muscles to determine peak
tissue velocity (e′) of the LV posterior wall. The ratio of these measures
(E/e′) was used as an indicator of diastolic function (60).
Histology and immunostaining. Isolated hearts were fixed for 4
hours in freshly diluted 4% paraformaldehyde at 4°C. Part of the tissue
was rinsed with PBS and cryoprotected in 30% sucrose/PBS overnight
before embedding in OCT (Tissue-Tek). Another part was washed with
70% ethanol and subjected to paraffin embedding. Afterwards, 10-μm
cryosections were collected and then blocked for 30 minutes at room
temperature in a blocking solution (PBS with 5% goat serum, 2% bovine
serum albumin, 0.1%Triton X-100). Sections were then incubated
with primary antibody against αSMA (Sigma-Aldrich, A2547) diluted
in blocking solution overnight at 4°C at 1:200 dilution. Sections were
washed 3 times for 5 minutes each in PBS and incubated with a 1:500
dilution of Alexa Fluor 568–conjugated (Life Technologies, A11031)
goat anti-mouse antibody for 2 hours at room temperature at 1:500 dilutions. After washing 3 times for 5 minutes each, sections were stained
with DAPI at a concentration of 0.1 μg/ml in PBS for 5 minutes at room
temperature and mounted on slides using aqueous mounting medium
(H-1400, Vector Laboratories). Cryosections were occasionally used to
visualize native EGFP fluorescence from the different genotypes with
the Rosa26-containing loxP-dependent reporter allele. Images were
acquired with an inverted Nikon A1R confocal microscope using NIS
Elements AR 4.13 software. Masson’s trichrome staining was performed
with a kit (Sigma-Aldrich, HT15-1KT) per the manufacturer’s instructions. Trichrome images were captured with a Leica M165FC stereo
microscope with fluorescence using a Leica DFC310 FX camera and the
Leica Application Suite. Picrosirius red staining was performed with a
kit (Abcam ab150681) per the manufacturer’s instructions. Picrosirius
red and polarized light images were captured at ×200 magnification by
an Olympus BX51 microscope equipped with a single chip color CCD
camera (DP70) and DP controller software (Olympus America Inc.).
Images were analyzed with Adobe Photoshop CS5.
Proliferation measurement. Six days after TAC, mice were treated
with EdU (61135-33-9, Santa Cruz Biotechnology Inc.) dissolved in
PBS with 2 separate i.p. injections over 24 hours (5 μg/g of body weight/
day). Four hours after the second EdU injection, hearts were fixed in
4% paraformaldehyde and frozen for immunohistochemical analysis. Cryosections were costained with anti-EGFP antibody (ab13970,
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Abcam) along with anti-CD31 (Miltenyi Biotec, 130-097-418) or antiErg1 (Abcam, Ab92513), then sections were incubated with a 1:500
dilution of goat anti-chicken Alexa Fluor 488 and goat anti-rabbit Alexa
Fluor 568 secondary antibodies (A-11039 and A-11036, Life Technologies), followed by EdU staining using a Click-iT EdU Alexa Fluor
647 Imaging Kit (C10643, Life Technologies). Pictures were taken
with a Nikon A1 confocal microscope. Three random pictures of the
left ventricle free wall were taken from 3 sections at different levels
for quantitative analysis. For myofibroblast proliferation, only EGFP/
EdU/DAPI-positive cells were counted. For endothelial cell proliferation, CD31/EdU/DAPI cells were counted.
Western blot. Western blotting was performed as described previously (61). Briefly, after electrophoresis and transfer to PVDF
membranes, the membranes were incubated with antibodies against
Smad2 (1:1000 Cell Signaling, 5339S), Smad3 (1:500 Abcam,
ab28379), Cre (1:1000 Novagen, 69050), EGFP (1:1000 Santa Cruz
Biotechnology Inc., SC-9996), Tgfbr2 (1:1000 Abcam, 186838), and
Gapdh (1:10000 Fitzgerald, 10R-G109a). PVDF membranes were
then incubated with the appropriate Alexa Fluor–conjugated secondary antibodies (Thermo Fisher Scientific, A-21057, A11367) and visualized using an Odyssey CLx imaging system (LI-COR Biosciences,
9140). Full and uncropped Western blot gel images for all the figures
are shown in Supplemental Figure 8.
Fibroblast cultures and treatments. Adult skin and heart fibroblasts
were cultured in DMEM (Fisher Scientific, SH30022FS) supplemented
with 10% FBS and nonessential amino acids. Depending on the experiment, cells were then infected with Adβ-gal or AdCre recombinase–
expressing adenovirus and maintained for 72 hours. Myofibroblast differentiation was analyzed by counting cells positive for αSMA stress fibers
by immunocytochemistry 24 hours after differentiation induction with
recombinant porcine TGF-β (10 ng/ml, 101-B1-001, R&D Systems). The
same procedure was used for collagen gel contraction assays, although 72
hours after infection, 50,000 cells were seeded into collagen gel matrices and then were induced to differentiate with 10 ng/ml of recombinant
TGF-β in DMEM media supplemented with 2% FBS. Gels were released,
and the area of contraction was measured after 24 additional hours.
Adult heart interstitial cell isolation. Adult cardiomyocytes were
isolated from freshly beating hearts cannulated for retrograde perfusion with a modified Tyrode solution (120 mM NaCl, 14.7 mM KCl, 0.6
mM KH2PO4, 0.6 mM Na2HPO4, 1.2 mM MgSO4, 10 mM HEPES, 4.6
mM NaHCO3, 30 mM taurine, 5.5 mM glucose, and 10 mM butanedionemonoxime [BDM], pH7.4) supplemented with Liberase TH
(Roche, 05401151001). After perfusion, hearts were disassociated
into cardiomyocytes and noncardiomyocyte fractions and aggregated
by 2 serial centrifugations at 10 g for 5 minutes at 4°C. The noncardiomyocyte cell fraction was collected after a final centrifugation at
500 g for 10 minutes at 4°C. Endothelial (CD31+) and myeloid (CD45+)
cell fractions were sorted with a Magnetic Cell Isolation and Cell Separation Kit (Miltenyi Biotec) with antibodies against CD31 (Miltenyi
Biotec, 130-097-418) and CD45 (Miltenyi Biotec, 130-052-301) using
the manufacturer’s recommended conditions.
Isolation of adult cardiac or skin fibroblasts. Cardiac ventricles
or patches of skin were excised from mice, rinsed with cold sterile
HBSS, and treated as described previously (29). Briefly, tissues were
thoroughly minced with sterile fine scissors and digested in 10 ml
DMEM containing Worthington collagenase type 2 (LS004177)
(0.2%) at 37°C for 90 minutes. During this incubation, the digesting
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tissue was triturated for a minute with a sterile serological pipette
every 15 minutes. The supernatant cell suspension containing liberated fibroblasts was then collected into a tube containing cold
DMEM. The undigested fraction was reconstituted with fresh digestion media, and the same digestion procedure was repeated until
almost the entire tissue was dissociated into single cells. Cell debris
was eliminated by 2 serial centrifugations at 10 g for 5 minutes at 4°C,
and the cell fraction was collected after a final centrifugation at 500 g
for 10 minutes at 4°C. Pellets were washed once with ice-cold HBSS
and resuspended in 2% FCS in HBSS and incubated on ice for FACS
analysis using a BD Aria Instrument. A fraction of this preparation
was cultured in DMEM media supplemented with 10% FBS on 0.1%
gelatin-coated plates for further in vitro analysis.
Flow cytometry and cell sorting. Flow cytometry analysis was performed on isolated cardiac interstitial cells using BD FACSCanto II
running FACSDiva software with the following configuration: 405 nm
laser for Alexa Fluor 405, 633 nm for APC, and 488 nm for EGFP. Voltages were determined using single-stain and fluorescence minus one
controls. Analysis was performed using FlowJo vX software (FLOWJO LLC). Cells were stained with APC-conjugated antibodies against
CD31 (eBioscience 17-0311-82) at a 1:200 dilution in 2% FCS in HBSS
incubated for 30 minutes on ice. Cells were then washed 3 times with
ice-cold HBSS and incubated for another 30 minutes on ice with 2%
FCS and 0.1% Triton-X 100 in HBSS containing secondary antibody
conjugated to Alexa Fluor 647. At the end of the incubation time, cells
were washed 3 times and analyzed. For analysis of lineage-traced genotypes, we utilized the endogenous EGFP fluorescence expressed by
the recombined reporter allele described above under Mice. The count
of EGFP+ cells was normalized to the number of CD31+ cells to assure
similar digestion of samples and to eliminate differences in total
counts due to sample preparation variability. Quantification of total
isolated CD31+ endothelial cells was also performed to assess proliferation in the different genotypes versus fibroblasts.
RNA-Seq and bioinformatic analysis. Total RNA was amplified
using the Ovation RNA-Seq System v2 (NuGEN, 7102-32) according
to the manufacturer’s protocol. The libraries were prepared with the
Nextera XT DNA Sample Preparation Kit (Illumina Technologies,
FC-131-1002). One nanogram of cDNA was suspended in Tagment
DNA Buffer, and tagmentation (fragmentation and tagging with the
adaptors) was performed with the Nextera enzyme (Amplicon Tagment Mix, FC-131-1096), incubating at 55°C for 10 minutes. Libraries
were prepared by PCR with the Nextera PCR Master Mix, and 2 Nextera Indexes (N7XX, and N5XX) according to the following program: 1
cycle of 72°C for 3 minutes; 1 cycle of 98°C for 30 seconds,; 12 cycles of
95°C for 10 seconds, 55°C for 30 seconds, and 72°C for 1 minute; and
1 cycle of 72°C for 5 minutes. The purified cDNA was captured on an
Illumina flow cell for cluster generation. Libraries were sequenced on
the Illumina HiSeq2500 following the manufacturer’s protocol. Bioinformatic analysis of data was carried out using Strand NGS software
(ver. 2.6; Build: mouse mm10 [UCSC] using Ensembl transcript annotations) to identify differentially expressed genes. Gene clustering
analysis of pathway gene expression groupings was done with Strand
NGS software. The RNA-Seq data were deposited in the NCBI’s Gene
Expression Omnibus (GEO GSE101772).
Reverse-transcriptase PCR. RNA was isolated from fibroblasts using
QIAshredder homogenization and the RNAeasy Kit according to the
manufacturer’s instructions (QIAGEN, catalog 74104). Total RNA was

reverse transcribed using random oligo-dT primers and a Verso cDNA
Synthesis Kit (Thermo Fisher, AB1453) according to the manufacturer’s
instructions. Real-time PCR was performed using SsoAdvanced SYBR
Green (Bio-Rad, 6090), and Rpl7 expression was used for normalization. The following primer sets were used to identify transcripts: collagen
1a1, 5′-AATGGCACGGCTGTGTGCGA and 5′-AACGGGTCCCCTTGGGCCTT; collagen 3a1, 5′-TCCCCTGGAATCTGTGAATC and
5′-TGAGTCGAATTGGGGAGAAT; periostin, 5′-ACGGAGCTCAGGGCTGAAGATG and 5′- GTTTGGGCCCTGATCCCGAC.
Cell death analysis. At 90% confluence, primary skin fibroblasts
were treated with 200 nM staurosporine for 36 hours or vehicle
(DMSO). Cell death was determined by the Muse Count & Viability
Assay (Millipore, MCH100102) as previously described (62). Briefly,
the medium was collected with the trypsin-liberated cells, which were
centrifuged and washed twice with PBS and then incubated with the
Muse Count & Viability reagent. The cells were then quantified on a
Muse cell analyzer (Millipore) at 5,000 counts per sample.
Statistics. One-way ANOVA with post hoc Tukey’s honest significant difference (HSD) or Student’s t test was used to determine statistical significance, depending on the type of data analyzed and number of
comparisons. P values of less than 0.05 were considered statistically significant. Averaged data are presented with SEM to indicate variability.
Study approval. Mice were observed daily and cages changed weekly
by certified veterinary technicians at Cincinnati Children’s Hospital
Medical Center. Mice were also closely assessed for their well-being,
monitored by adequate physical activity and food intake on a daily
basis. Housing conditions and husbandry conformed to AAALAC standards as well as the standard guidelines from the NIH Office of Laboratory Animal Welfare (http://grants.nih.gov/grants/olaw/animal_use.
htm). The institution also retains ongoing certification by AAALAC.
All animal experimentation and this specific study were approved
by the Office of Research Compliance and Regulatory Affairs and by
the Cincinnati Children’s Hospital Institutional Animal Care and Use
Committee (protocol number IACUC 2016-0069, expires 11-2019).
No human subjects were used.
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